Experiment 67095
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Salix alba (SALICACEAE) |
| Citation | WAGNER,I: BIEGERT,C: SCHMID,B: HEIDE,L:. (2000). WILLOW BARK IN THE TREATMENT OF RHEUMATIC DISORDERS:RANDOMIZED CLINICAL TRIALS.. 7(2) |
| Amount utilized | |
| Compound isolated | |
| Disease | 6-WEEK, PLACEBO- AND STANDARD-CONTROLLED TRIAL IN OUTPATIENTS WITH OSTEOARTHRITIS:THIS TRIAL IS NOW IN PREPERATION IN ORDER TO CONFIRM THE RESULT OF THE PREVIOUS, INPATIENT TRIAL IN AN OUTPATIENT POPULATION, TO INVESTIGATE THE TREATMENT EFFECT IN A LONGER TREATMENT PERIOD AND TO COMPARE THE EFFECT OF WILLOW BARK EXTREACT WITH THAT OF A STANDARD NSAID SUCH AS DICLOFENAC. PRIMARY OUTCOME MEASURE WILL BE THE PAIN DIMENSION OF THE WOMAC INDEX. SECONDARY OUTCOME MEASURES INCLUDE STIFFNESS AND PHYSICAL FUNCTION DIMENSIONS OF THE WOMAC, PATIENT'S AND PHYSICIAN'S OVERALL ASSESSMENT AND A QUALITY OF LIFE INDEX(SF-36). |
| Dose amount | 240.0 MG |
| Number | 2 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | TYPE EXT NOT STATED |
| Gender | GIVEN TO BOTH SEXES |